Neuland Laboratories Limited announced its financial results for the first quarter of FY27, reporting a significant year-over-year increase in total income to ₹650.1 crore, up 116.3%. EBITDA also saw substantial growth, reaching ₹231.1 crore, a 448.2% increase compared to the previous year. The company highlighted encouraging performance across its businesses and anticipates further investment based on emerging opportunities.
Neuland Laboratories Reports Strong Q1 FY27 Financials
Neuland Laboratories Limited has announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company reported a robust performance, with its Total Income reaching ₹650.1 crore. This represents a significant year-over-year (YoY) increase of 116.3% compared to ₹300.6 crore in Q1 FY26.
EBITDA and Profitability Growth
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also demonstrated substantial growth, standing at ₹231.1 crore in Q1 FY27. This is a 448.2% increase from ₹42.1 crore in the corresponding quarter of the previous fiscal year. The EBITDA Margin for the quarter was 35.5%, an improvement from 14.0% in Q1 FY26.
Profit Before Tax (PBT) for Q1 FY27 was ₹197.5 crore, marking a substantial 1036.7% increase from ₹17.4 crore in Q1 FY26. The Profit After Tax (PAT) also surged to ₹147.4 crore, a 975.0% increase over ₹13.7 crore in the prior year’s quarter. Correspondingly, the PAT Margin improved to 22.7% from 4.6% in Q1 FY26.
CEO Commentary and Future Outlook
Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, commented on the performance, stating, “Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year.” He further noted that while Commercial Products contributed most of the revenue, exciting developments are occurring in pipeline projects. The company is focusing on building customer confidence and long-term partnerships, with significant Capex projects proceeding as planned. Mr. Davuluri anticipates an increase in investment intensity based on available opportunities.
Quarter-over-Quarter Performance
On a quarter-over-quarter (QoQ) basis, Total Income decreased by 17.6% from ₹788.7 crore in Q4 FY26 to ₹650.1 crore in Q1 FY27. Similarly, EBITDA saw a QoQ decline of 27.6%, falling from ₹319.4 crore to ₹231.1 crore. The EBITDA Margin also decreased by 500 basis points QoQ to 35.5%.
Profit Before Tax decreased by 31.2% QoQ, and Profit After Tax decreased by 30.6% QoQ. Earnings Per Share (EPS) for the quarter was ₹114.9, down 30.6% from ₹165.6 in Q4 FY26.
Earnings Call Information
Neuland Laboratories will conduct a one-hour Earnings Call on Wednesday, August 5, 2026, at 17:30 hrs IST. Management will discuss the company’s performance and answer participant questions. Registration details and a webcast link are provided for interested parties.
Source: BSE
